Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Accumulated Expenses: 2012-2025

Historic Accumulated Expenses for Aytu Biopharma (AYTU) over the last 13 years, with Jun 2025 value amounting to $38.2 million.

  • Aytu Biopharma's Accumulated Expenses rose 8.83% to $36.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $36.7 million, marking a year-over-year increase of 8.83%. This contributed to the annual value of $38.2 million for FY2025, which is 0.06% up from last year.
  • According to the latest figures from FY2025, Aytu Biopharma's Accumulated Expenses is $38.2 million, which was up 0.06% from $38.1 million recorded in FY2024.
  • In the past 5 years, Aytu Biopharma's Accumulated Expenses ranged from a high of $57.2 million in FY2021 and a low of $38.1 million during FY2024.
  • Over the past 3 years, Aytu Biopharma's median Accumulated Expenses value was $38.2 million (recorded in 2025), while the average stood at $41.0 million.
  • In the last 5 years, Aytu Biopharma's Accumulated Expenses spiked by 548.10% in 2021 and then decreased by 22.80% in 2022.
  • Over the past 5 years, Aytu Biopharma's Accumulated Expenses (Yearly) stood at $57.2 million in 2021, then decreased by 22.80% to $44.2 million in 2022, then climbed by 5.91% to $46.8 million in 2023, then fell by 18.50% to $38.1 million in 2024, then climbed by 0.06% to $38.2 million in 2025.